P 017
Alternative Names: NBG-017; P-017Latest Information Update: 07 Oct 2021
At a glance
- Originator NB Health Laboratory
- Class Antihypoglycaemics; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Hypoglycaemia; Pancreatic cancer
Highest Development Phases
- Research Hypoglycaemia; Pancreatic cancer
Most Recent Events
- 28 Sep 2021 Early research in Hypoglycaemia in Japan (Parenteral) before September 2021 (NB Health Laboratory pipeline, September 2021)
- 28 Sep 2021 Early research in Pancreatic cancer in Japan (Parenteral) before September 2021 (NB Health Laboratory pipeline, September 2021)
- 29 Nov 2016 NB Health Laboratory has patent protection for Anti-human CCR7 antibody, hybridoma, nucleic acid, vector, cell, pharmaceutical composition, and antibody-immobilized carrier in the US